Monopar Therapeutics (MNPR) News Today $25.82 +2.03 (+8.53%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Monopar Therapeutics prices 798,655 shares at $23.79 in registered offeringDecember 21 at 3:50 AM | markets.businessinsider.comMonopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded WarrantsDecember 20 at 9:00 AM | globenewswire.comHere's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price StrengthDecember 18, 2024 | msn.comMonopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-LuDecember 5, 2024 | globenewswire.comMonopar to Present at the 36th Annual Piper Sandler Healthcare ConferenceDecember 3, 2024 | markets.businessinsider.comMonopar to Present at the 36th Annual Piper Sandler Healthcare ConferenceDecember 3, 2024 | globenewswire.com3 Momentum Stocks Soaring Into 2025 and Beyond (MNPR)Given the S&P's strong performance in the last year, momentum stock plays are those that have exceeded that high bar; here are three companies with potential.December 3, 2024 | marketbeat.comMonopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In FocusNovember 25, 2024 | seekingalpha.comJones Trading raises Monopar Therapeutics target to $37November 21, 2024 | uk.investing.comMonopar Therapeutics Gains Buy Rating Following Strategic Agreement and Promising Phase III Results for Wilson’s Disease TreatmentNovember 20, 2024 | markets.businessinsider.comMonopar Therapeutics price target raised to $37 from $9 at JonesResearchNovember 20, 2024 | markets.businessinsider.comWhat is HC Wainwright's Estimate for MNPR FY2024 Earnings?Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright increased their FY2024 earnings estimates for Monopar Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the company will earn ($1November 14, 2024 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Given New $22.00 Price Target at HC WainwrightHC Wainwright boosted their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the stock a "buy" rating in a report on Monday.November 11, 2024 | marketbeat.comTransformative Licensing Acquisition Drives Buy Rating for Monopar TherapeuticsNovember 11, 2024 | markets.businessinsider.comMonopar Therapeutics price target raised to $22 from $6 at H.C. WainwrightNovember 11, 2024 | markets.businessinsider.comMonopar Therapeutics Inc.: Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | finanznachrichten.deMonopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | markets.businessinsider.comMonopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) CFO Acquires $25,187.50 in StockOctober 31, 2024 | insidertrades.comMonopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common StockOctober 30, 2024 | globenewswire.comMonopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common StockOctober 28, 2024 | globenewswire.comMonopar Therapeutics Inc. Announces Proposed Public Offering of Common StockOctober 28, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Drop in Short InterestMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 49,900 shares, a drop of 55.6% from the September 30th total of 112,400 shares. Currently, 2.8% of the company's stock are short sold. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 0.0 days.October 27, 2024 | marketbeat.comIndividual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last weekOctober 26, 2024 | finance.yahoo.comMarketBeat Week in Review – 10/21- 10/25 (MNPR)Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatilityOctober 26, 2024 | marketbeat.comWhat's Going On With Monopar Therapeutics Shares Friday?October 26, 2024 | msn.comMonopar Therapeutics (NASDAQ:MNPR) Shares Gap Down - Time to Sell?Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down - Time to Sell?October 25, 2024 | marketbeat.comMonopar Therapeutics Skyrockets 400% on Licensing DealMonopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.October 25, 2024 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Sets New 52-Week High - Should You Buy?Monopar Therapeutics (NASDAQ:MNPR) Reaches New 1-Year High - Here's WhyOctober 24, 2024 | marketbeat.comMonopar Shares Rise on AstraZeneca Licensing DealOctober 24, 2024 | marketwatch.comMonopar Shares Surge on AstraZeneca Licensing Deal -- UpdateOctober 24, 2024 | marketwatch.comMonopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug CandidateOctober 24, 2024 | markets.businessinsider.comMonopar Therapeutics Unveils Promising Radiopharmaceutical DataOctober 22, 2024 | markets.businessinsider.comMonopar Therapeutics presents data from radiopharma program based on MNPR-101October 22, 2024 | markets.businessinsider.comMonopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024October 22, 2024 | globenewswire.comMonopar Therapeutics Expands Portfolio with New Patent FilingOctober 16, 2024 | finance.yahoo.comMonopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and LinkersOctober 15, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Decrease in Short InterestMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totalling 112,400 shares, a drop of 82.8% from the September 15th total of 652,500 shares. Approximately 6.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 806,900 shares, the short-interest ratio is presently 0.1 days.October 10, 2024 | marketbeat.comMonopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer TrialOctober 8, 2024 | finance.yahoo.comMonopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced CancersOctober 7, 2024 | markets.businessinsider.comMonopar Therapeutics (NASDAQ:MNPR) Stock, Short Interest ReportOctober 2, 2024 | benzinga.comMonopar Therapeutics (NASDAQ:MNPR) Stock, Insider Trading ActivityOctober 1, 2024 | benzinga.comMONOPAR THERAP. NEW (1IY0.MU)September 12, 2024 | ca.finance.yahoo.comMonopar Shares Rise After Clinical Data on Cancer TreatmentSeptember 12, 2024 | marketwatch.comMonopar Therapeutics Inc.: Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrSeptember 12, 2024 | finanznachrichten.deMonopar Therapeutics Soars Over Announcement Of Positive Data From MNPR-101-Zr Phase 1 TrialSeptember 12, 2024 | markets.businessinsider.comWhy Monopar Therapeutics (MNPR) Stock Is Skyrocketing TodaySeptember 12, 2024 | msn.comMonopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrSeptember 12, 2024 | globenewswire.comMonopar to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comMonopar Regains Compliance with Nasdaq Minimum Bid Price RuleAugust 27, 2024 | globenewswire.com Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address If you see ONE chart today… make it this one (Ad)$1 Trillion… That’s how much Big Tech is set to spend on AI investment in the coming months—according to Goldman Sachs. This investment is driving an A.I. boom that’s being felt across many industries… Including a specific group of energy tickers since A.I. data centers use a massive amount of power. One of those tickers is CEG, up nearly 600% in the last 3 years… Combined with the upcoming presidential election, we have the recipe for a major shakeup in the market. You see, each time the U.S. elects a new president, one overlooked part of the energy sector tends to see a big move. Fact is… this energy niche is BOOMING. And expects this underappreciated niche to continue rallying well into 2026. MNPR Media Mentions By Week MNPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼0.850.60▲Average Medical News Sentiment MNPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼32▲MNPR Articles Average Week Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Phathom Pharmaceuticals News ProKidney News Annexon News Ginkgo Bioworks News Astria Therapeutics News Humacyte News PureTech Health News AnaptysBio News Mereo BioPharma Group News CorMedix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MNPR Stock Alerts